PMID- 37422155 OWN - NLM STAT- Publisher LR - 20231006 IS - 1530-891X (Print) IS - 1530-891X (Linking) VI - 29 IP - 10 DP - 2023 Oct TI - Trends and Gaps in Statin Use for Cardiovascular Disease Prevention in Type 2 Diabetes: A Real-World Study in Shanghai, China. PG - 747-753 LID - S1530-891X(23)00470-6 [pii] LID - 10.1016/j.eprac.2023.07.001 [doi] AB - BACKGROUND: Cardiovascular disease (CVD) is the major cause of death among persons with diabetes. As the preventative use of statin has been proved to reduce CVD risks, understanding the current status and the trend in statin use is crucial to improve clinical treatment strategies. OBJECTIVE: Our study aimed to answer the question of what were the status and trend of statin use in Shanghai, China. METHODS: Our study estimated statin use and trends from 2015 to 2021 among 702 727 patients with type 2 diabetes mellitus (T2DM) based on electronic health records from the Shanghai Hospital Link Database. Patients were grouped according to the presence of CVDs, tested separately for statin primary and secondary prevention use, and stratified by age and sex. RESULTS: In the study population, 221 127 patients (31.5%) received statin therapy, and among patients with CVD, 157 622 patients (51.62%) received statin therapy for secondary prevention, but only 15% of patients received statins for primary prevention. The trend in the use of statins was still on the rise from 28.3% in 2015. Statin use increased with age (18-39 years, 14.0%; 40-59 years, 26.8%; 60-74 years, 33.35%; and 75 and over, 36.1%), and women (29.7%, n = 93 977) were less likely to receive statin therapy compared to men (32.9%, n = 127 150). CONCLUSION: Despite the rise in statin use in T2DM in recent decades, a large proportion of subjects with T2DM did not receive statin therapy. CI - Copyright (c) 2023 AACE. Published by Elsevier Inc. All rights reserved. FAU - Jing, Renjie AU - Jing R AD - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the People's Republic of China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Yao, Huayan AU - Yao H AD - Computer Net Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Yan, Qun AU - Yan Q AD - Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Xue, Yanbin AU - Xue Y AD - Computer Net Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Sun, Wen AU - Sun W AD - Wonders Information Co Ltd, Shanghai, China. FAU - Lu, Ping AU - Lu P AD - Wonders Information Co Ltd, Shanghai, China. FAU - Zhang, Zizheng AU - Zhang Z AD - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the People's Republic of China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Xie, Rui AU - Xie R AD - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the People's Republic of China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Cui, Bin AU - Cui B AD - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the People's Republic of China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: cb11302@rjh.com.cn. FAU - Feng, Bo AU - Feng B AD - Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. Electronic address: fengbodfyy@tongji.edu.cn. LA - eng PT - Journal Article DEP - 20230707 PL - United States TA - Endocr Pract JT - Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists JID - 9607439 SB - IM OTO - NOTNLM OT - real-world data OT - statin OT - type 2 diabetes mellitus COIS- Disclosure The authors have no multiplicity of interest to disclose. EDAT- 2023/07/09 01:07 MHDA- 2023/07/09 01:07 CRDT- 2023/07/08 19:27 PHST- 2023/05/10 00:00 [received] PHST- 2023/06/14 00:00 [revised] PHST- 2023/07/03 00:00 [accepted] PHST- 2023/07/09 01:07 [pubmed] PHST- 2023/07/09 01:07 [medline] PHST- 2023/07/08 19:27 [entrez] AID - S1530-891X(23)00470-6 [pii] AID - 10.1016/j.eprac.2023.07.001 [doi] PST - ppublish SO - Endocr Pract. 2023 Oct;29(10):747-753. doi: 10.1016/j.eprac.2023.07.001. Epub 2023 Jul 7.